EcoDrugPlus

Cyclin Dependent Kinase 4

Ensembl ID : ENSCSEG00000004292
Gene Symbol: CDK4
3 Cross references
239 Possible Orthologues:

Cyclin Dependent Kinase 5

Ensembl ID : ENSCSEG00000011124
Gene Symbol: CDK5
3 Cross references
169 Possible Orthologues:

Cyclin Dependent Kinase 6

Ensembl ID : ENSCSEG00000012577
Gene Symbol: CDK6
3 Cross references
200 Possible Orthologues:

Cyclin Dependent Kinase 7

Ensembl ID : ENSCSEG00000016446
Gene Symbol: CDK7
3 Cross references
219 Possible Orthologues:

Cyclin Dependent Kinase 9

Ensembl ID : ENSCSEG00000009903
Gene Symbol: CDK9
3 Cross references
207 Possible Orthologues:

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSCSEG00000018252
Gene Symbol: LOC103391357
3 Cross references
180 Possible Orthologues:

Cytidine Deaminase

Ensembl ID : ENSCSEG00000005144
Gene Symbol: CDA
3 Cross references
199 Possible Orthologues:

Cytochrome P450 26a1

Ensembl ID : ENSCSEG00000011422
Gene Symbol: LOC103381669
3 Cross references
194 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSCSEG00000002669
Gene Symbol: LOC103387007
2 Cross references
466 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSCSEG00000002662
Gene Symbol: LOC103387006
2 Cross references
560 Possible Orthologues:

Cytochrome P450 3a56-Like

Ensembl ID : ENSCSEG00000002180
Gene Symbol: LOC103383478
3 Cross references
571 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSCSEG00000010049
Gene Symbol: CYP19A1
4 Cross references
246 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).